Table 2.
Clinical information and recording details.
| ID | Age range (y) | Sex | Disease duration (y) | UPDRS pre-DBS OFF/ON MED | UPDRS OFF/ON DBS, OFF MED at 3 months follow-up | Time of recording (days post-surgery [duration]) | Stimulation amplitude (mA) | Peak frequency (Hz) | LEDD at time of recording |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 61–65 | F | 10 | 50/9 | 22/15 | 43–74 (31) |
R:2.2–2.8 L:0.1–0.2 |
R: 25.39 L: 19.53 |
575 mg |
| 2 | 66–70 | M | 11 | 63/30 | 48/34 | 123–155 (32) |
R:0.5 L:0.5 |
R: 27.34c L: 16.60 |
1175 mg |
| 3 | 56–60 | F | 15 | 37/23 | 29/20 | 32–64 (32) |
R:1.4–1.6 L:1.4–1.8 |
R:25.39 L:13.67 |
100 mg |
| 4 | 61–65 | F | 6 | 50/33 | 40/19 | 73–91 (18) |
R: 1 L: 1 |
R: 14.65 L: 18.55c |
300 mg |
| 5 | 66–70 | M | 15 | 66/27 | 39/14 | 37–96 (59) +21b | R:2–2.8 | R: 15.63 | 300 mg |
| 6 | 56–60 | M | 8 | 23/4 | 28/11 | 116–148 (32) |
R:1.7–2 L:1.7–2 |
R:22.46 L: 20.51 |
175 mg |
| 7 | 56–60 | M | 11 | 72/39 | 47/33a | 393–396 (3) |
R: 1.2 L: 2 |
R: 20.51 L: 6.84 |
711 mg |
| 8 | 66–70 | F | 11 | 49/30 | N/A | 10–20 (10) |
R:0-1 L:0-1 |
R: 23.44 L: 7.81 |
580 mg |
| 9 | 71–75 | M | 15 | 67/43 | N/A | 8–19 (11) |
R: 0.5–1.5 L: 0.5–1.5 |
R: 15.63 L: 7.81 |
575 mg |
| 10 | 66–70 | M | 18 | 40/25 | N/A | 8–14 (6) |
R:0.5 L:0.5 |
R: 7.81 L: 13.67 |
800 mg |
| 11 | 56–60 | M | 13 | 68/39 | N/A | 10–14 (4) |
R: 1 L: 1 |
R: 7.81 L: 13.67 |
900 mg |
Information on the participants included in this study. Age at surgery, sex (F female, M male), disease duration in years. MDS-UPDRS Part III for OFF medication/ON medication state at the pre-DBS evaluation and during OFF Medication/DBS OFF/ON at 3 months follow-up for patients 1–6 and 12 months follow-up for patient 7. Patients 1–6 were included in the long-term analysis, while in patients 7–11 beta/theta band activity was recorded simultaneously around the 12 months follow-up (patient 7) or in a subacute post-surgical phase (patients 8–11). Accordingly, LEDD are presented at the time of discharge from the 12 months follow-up for patient 7, after surgery for patients 8–11 and at the admission for 3 months follow-up for patients 1–6. Stimulation amplitude was either set to a single value or was allowed to vary within the given range during the recording period. Peak frequency for chronic sensing was set within the beta range on all STNs under investigation for patients 1–6, while for patients 7–11 one STN was recorded in the theta frequency range respectively.
aAt 12 months follow-up.
bAdditional data were collected to investigate beta power across sleeping and waking periods (not in the main data set).
cSTN was excluded from analysis because of ECG contamination.